Gheuens Sarah sold $151K of AGIO

Gheuens Sarah (Chief Medical Officer) sold 4,007 shares of AGIOS PHARMACEUTICALS, INC. (AGIO) at $37.56 ($0.15M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gheuens Sarah
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AGIO
Neutral
high confidence
Mentioned
$AGIO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGIONeutralLow
01

Why it matters

The disclosed event is an officer open-market sale executed under a pre-arranged 10b5-1 plan, with no new company fundamentals included.

02

Market read

Traders may monitor insider activity for sentiment, but this specific filing lacks new operational or regulatory catalysts.

03

What to watch

The article provides no context on total holdings, prior sales frequency, or whether other insiders are selling, limiting inference beyond the mechanical disclosure.

Relevance 3/10Novelty 2/10Timing: Filed 2026-07-02, describing a sale executed 2026-07-01.

Background

The article is an SEC Form 4 insider transaction disclosure for Agios Pharmaceuticals, Inc.

Company-level read

Ticker impact

$AGIONeutralHigh confidence
Context

Agios Pharmaceuticals CMO Sarah Gheuens sold 4,007 shares on 2026-07-01 at $37.56 via a 10b5-1 plan, per Form 4.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven rather than fundamental.

Evidence & confidence

The filing discloses transaction size, price, and that it was executed under a pre-arranged 10b5-1 plan, with no accompanying company-specific operational or regulatory catalyst.

Market effects

No direct sector read-through; this is a single insider transaction without new clinical, regulatory, or product information.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with private views on valuation or liquidity needs, so some traders may treat it as a mild bearish signal.

Key entities

  • AGIOS PHARMACEUTICALS, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Gheuens Sarah

    Chief Medical Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AGIOMed

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty

Agios Pharmaceuticals (AGIO) reported Q3 revenue of $55.4M, up from $12.9M a year earlier, driven by strong AQVESME adoption. The company saw 177 new prescriptions, with 75% patient persistence. International revenue rose 74% to $6.6M. Agios prepares for a potential sickle cell launch, but faces FDA review extension and higher expenses. Q3 net loss narrowed to $65M from $103M YoY.

$AGIOMed

Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue surged 4x, but faced a 3-month FDA review delay for mitapivat in sickle cell disease, increasing uncertainty. Net loss narrowed to $65M from $103.4M YoY. Selling expenses rose to $56.5M, and no 2027 guidance was provided. Thalassemia launch growth may moderate, with 177 prescriptions as a new run rate. Pipeline programs remain early-stage.

$AGIOMed

Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Agios Pharmaceuticals reported Q3 2026 revenue of $55.4M, driven by mitapivat in thalassemia. The company plans to cut R&D headcount by 35% to focus on rare hematology and aims for non-GAAP profitability in 2028. Mitapivat's sickle cell disease approval was delayed to February 2027 due to FDA review. The company is also advancing AG-236 for polycythemia vera and cevidoplenib for immune thrombocytopenia.

$AGIOMed

Agios (AGIO) Q3 2026 Earnings Call Transcript

Agios (AGIO) reported Q3 2026 earnings, highlighting $55.4M in mitapivat revenue, a 3-month FDA review extension for sickle cell disease, and $907M in cash. The company plans to reduce R&D headcount by 35% and aims for non-GAAP profitability in 2028. Mitapivat saw a 4x revenue increase YoY, with strong U.S. and international demand.

$AGIOHigh

Truist cuts Agios Pharma stock price target on SCD concerns

Truist Securities reduced its price target for Agios Pharmaceuticals (NASDAQ: AGIO) to $35 from $37, citing concerns about sickle cell disease. The stock is currently trading at $28.38, down 15.7% over the past week. Agios reported Q3 2026 earnings that missed expectations, but revenue exceeded estimates. The company announced a 35% reduction in R&D headcount, aiming for non-GAAP profitability in 2028.

$AGIOHigh

Agios Q3 Mitapivat Revenue Surges More Than Fourfold; Sickle Cell FDA Decision Set For February 2027

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue of $55.4M for mitapivat products, up over fourfold YoY. U.S. revenue rose to $48.7M, while ex-U.S. revenue increased to $6.6M. Net loss narrowed to $65.0M. The FDA extended the PDUFA goal date for mitapivat in sickle cell disease to February 2027. Agios plans to reduce R&D workforce by over 35% by year-end 2026.